Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility
JAMA Network Open · 24.02.2023 · 6 (2) · e230698
DOI: 10.1001/jamanetworkopen.2023.0698 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 24.02.2023. Verfasst von Daichi Fujimoto und 21 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine III, Wakayama Medical University, Wakayama, Japan. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Chemoimmunotherapy is the standard first-line therapy for patients with extensive-stage small cell lung cancer (ES-SCLC). However, whether findings from pivotal trials can be extrapolated to the clinical practice setting remains unclear.
Objective
To compare treatment outcome gaps following first-line chemoimmunotherapy for patients with ES-SCLC between those who met and did not meet the eligibility criteria used in previous clinical trials. Design, Setting, and Participants A prospective cohort study was conducted from September 1, 2019, to September 30, 2020, at 32 hospitals in Japan, with at least 12 months of follow-up. Participants included consecutive patients with ES-SCLC who received carboplatin and etoposide with atezolizumab as first-line therapy. Exposures Patients who met eligibility criteria for pivotal phase 3 clinical trials were considered trial-eligible. Main Outcomes and Measures The primary outcome was 6-month progression-free survival. The secondary outcomes were differences in progression-free survival, overall survival, and safety according to whether key clinical trial eligibility criteria were met.
Results
A total of 207 patients were analyzed (median age, 72 years; range, 46-87 years; 170 [82%] were male). Sixty-four patients (31%) were older adults (age ≥75 years), and most (184 [89%]) had an Eastern Cooperative Oncology Group performance status of 0 or 1. There were 132 (64%) trial-eligible patients. The 6-month progression-free survival rate for all patients was 38.8% (95% CI, 32.4%-45.7%). The median progression-free survival was 5.1 months in trial-eligible patients and 4.7 months in trial-ineligible patients (hazard ratio, 0.72; 95% CI, 0.53-0.97; P = .03). The proportion of patients who achieved disease control was 93% (118 of 127) in trial-eligible patients and 77% (55 of 71) in trial-ineligible patients ( P = .002). The median overall survival was 15.8 months in trial-eligible patients and 13.1 months in trial-ineligible patients (hazard ratio, 0.73; 95% CI, 0.51-1.07; P = .10). The rate of severe adverse events was numerically higher among trial-ineligible patients than among trial-eligible patients (39% vs 27%; P = .07). Conclusions and Relevance In this cohort study, the overall treatment outcome was comparable to that reported in pivotal clinical trials. However, treatment outcomes after chemoimmunotherapy might differ between trial-eligible and trial-ineligible patients. These findings suggest that trial-eligibility criteria may be useful in clinical practice, and further studies using data from clinical practice settings are required to inform regulatory approval and clinical decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
- Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan.
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
- Division of Thoracic Oncology, Kobe Minimally Invasive Cancer Center, Kobe, Japan.
- Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.
- Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Zitieren
APA
Fujimoto, D., Morimoto, T., Tamiya, M., Hata, A., Matsumoto, H., Nakamura, A., Yokoyama, T., Taniguchi, Y., Uchida, J., Sato, Y., Yokoi, T., Tanaka, H., Furuya, N., Masuda, T., Sakata, Y., Miyauchi, E., Hara, S., Saito, G., Miura, S., …, & Akamatsu, H. (2023). Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility. JAMA Network Open, 6(2), e230698. https://doi.org/10.1001/jamanetworkopen.2023.0698
Vancouver
Fujimoto D, Morimoto T, Tamiya M, Hata A, Matsumoto H, Nakamura A, et al. Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility. JAMA Network Open. 2023;6(2):e230698. doi:10.1001/jamanetworkopen.2023.0698
BibTeX
@article{Fujimoto2023,
author = {Fujimoto, Daichi and Morimoto, Takeshi and Tamiya, Motohiro and Hata, Akito and Matsumoto, Hirotaka and Nakamura, Atsushi and Yokoyama, Toshihide and Taniguchi, Yoshihiko and Uchida, Junji and Sato, Yuki and Yokoi, Takashi and Tanaka, Hisashi and Furuya, Naoki and Masuda, Takeshi and Sakata, Yoshihiko and Miyauchi, Eisaku and Hara, Satoshi and Saito, Go and Miura, Satoru and Kanazu, Masaki and Yamamoto, Nobuyuki and Akamatsu, Hiroaki},
title = {Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility},
journal = {JAMA Network Open},
year = {2023},
volume = {6},
number = {2},
pages = {e230698},
doi = {10.1001/jamanetworkopen.2023.0698}
}
EUVIMED